tbuckley/cabot-search huggingface dataset:
Prognostic Relevance of Recurrent Genetic Aberrations in Pediatric Acute Megakaryoblastic Leukemia
Authors: Jasmijn de Rooij, Riccardo Masetti, Marry M. van den Heuvel-Eibrink, Jean-Michel Cayuela, Jan Trka, Dirk Reinhardt, Edwin Sonneveld, Todd A. Alonzo, Maarten Fornerod, Martin Zimmermann, Martina Pigazzi, Rob Pieters, Soheil Meshinchi, C. Michel Zwaan, Franco Locatelli
Journal: Blood (2015)
Effectiveness of Subcutaneous Low-Dose Alemtuzumab and Rituximab Combination Therapy for Steroid-Resistant Chronic Graft-Versus-Host Disease
Authors: Cesar H Gutiérrez-Aguirre, Juan A. Flores-Jiménez, Olga Cantú-Rodríguez, Jorge Cuervo-Sierra, Adrián A. Ceballos-López, Ramón A Martínez-Hernández, David Gómez-Almaguer
Journal: Blood (2011)
TCT-510 Five-year true serial evaluation of jailed side branches by Absorb bioresorbable vascular scaffolds using three-dimensional optical coherence tomography
Authors: Yoshinobu Onuma, Maik J. Grundeken, Shimpei Nakatani, Yohei Sotomi, Hector M. Garcia-Garcia, Takayuki Okamura, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2015)
Mutations in Tropomyosin 4 Cause Macrothrombocytopenia in Mice and Humans
Authors: Irina Pleines, Joanne Woods, Ernest Turro, Nicola Foad, Stephane Chappaz, Rachael M. Lane, Harriet Manning, Galina Schevzov, Sarah K Westbury, Andrew D Mumford, Remi Favier, Peter Gunning, Willem H. Ouwehand, Marloes R Tijssen, Benjamin T Kile
Journal: Blood (2014)
CD19 CAR-T Cells Administered after High-Dose Cyclophosphamide Chemotherapy Induce Rapid Remissions of Chemotherapy-Refractory Acute B-Cell Leukemia with High Tumor Burden
Authors: Yongxia Hu, Lei Xiao, Zhao Wu, Yi Luo, Chengfei Pu, Guoqing Wei, He Huang
Journal: Blood (2015)
TCT-348 Optical coherence tomographic evaluation of very acute change of coronary stent implanted in acute coronary syndrome patients
Authors: Yoshiro Tsukiyama, Amane Kozuki, Toshiro Shinke, Hiromasa Otake, Yoichi Kijima, Tomoya Masano, Ryoji Nagoshi, Kimitake Imamura, Hiroyuki Shibata, Kenichi Yanaka, Shinsuke Nakano, Junya Shite, Ken-ichi Hirata
Journal: Journal of the American College of Cardiology (2015)
<i>VHL</i>-mutant renal cell carcinomas contain cancer cells with mesenchymal phenotypes.
Authors: Craig Gedye, Danylo Sirskyj, Nazleen Carol Lobo, Andrew Evans, Neil Eric Fleshner, Michael Robinette, Alexandre Zlotta, Robert Hamilton, Girish S. Kulkarni, Antonio Finelli, Brenda L. Gallie, Michael A. S. Jewett, Laurie Ailles
Journal: Journal of Clinical Oncology (2013)

4568 Background: To study “cancer stem cells” it is imperative to account for all stromal cell populations within the tumour. The existence of “cancer stem cells” in clear cell renal cell carcinoma (ccRCC) has not been examined in ex vivo patient samples. Methods: We established a multiplex flow cytometry (FC) antibody panel in ccRCC, which reliably identified stromal lineages including CD45+ immune, CD31+/CD144+ endothelial and fibroblast-marker-positive subpopulations, thus allowing isolation of "lineage-negative" tumor cells. To verify the identity of tumour-derived populations as either cancer cells or normal stromal cells, we took advantage of the fact that mutations in VHL occur early during ccRCC tumorigenesis and are found in two-thirds of patients. Results: We sequenced 18 patient tumor samples, 12 of which had VHL exome mutations. Targeted re-sequencing of FC sorted subpopulations from these patients’ samples revealed that while CD45+ immune cells and CD31+/CD144+ endothelial cells were genetically normal, a population of VHL-mutant fibroblast-marker positive cells was consistently identified in every patient’s tumour. Immunohistochemistry showed that fibroblast marker-positive VHL-mutant cells do not have the large “clear cell” morphology typical of the majority of the cancer cells in these tumours. When purified and cultured, these fibroblast marker-positive VHL-mutant cells proliferate extensively under mesenchymal culture conditions, but displayed different morphologies to lineage-negative VHL-mutant tumor cells. Functional characterization of these FC sorted cell subpopulations is ongoing, including proliferation, migration, invasion, differentiation and treatment resistance. Conclusions: The phenotype and preliminary functional characterization of these VHL-mutant fibroblast-marker positive cells suggests a mesenchymal differentiation program in ccRCC, with implications for the ontogeny, biology and clinical management of VHL-mutant renal cancer.
A dose-finding study of temsirolimus and liposomal doxorubicin for patients with advanced soft tissue or bone sarcoma.
Authors: D. M. Loeb, K. A. DeLorenzo, A. R. S. Chen, C. F. Meyer, J. Powell
Journal: Journal of Clinical Oncology (2011)

10026 Background: Treatment options for patients with advanced sarcomas are limited, and new therapies are urgently needed. The cancer stem cell hypothesis predicts the existence of a chemotherapy-resistant population of tumor cells capable of generating and maintaining the bulk tumor population. Our laboratory has recently identified such a population in Ewing’s sarcoma, and we found that inhibition of mTOR signaling reverses the resistance of these cells to doxorubicin. We therefore hypothesize that treatment with liposomal doxorubicin and an mTOR inhibitor will improve survival of patients with advanced sarcoma, and have determined the maximum tolerated dose of this combination in these patients. Methods: Patients aged ≥ 1 year old with histologically confirmed recurrent or refractory sarcoma and adequate organ function were eligible. The first cohort of patients was treated with a standard dose of liposomal doxorubicin (30 mg/m2 every 28 days) and a standard dose of temsirolimus (15 mg/m2 weekly). Subjects were enrolled in cohorts of 3, and a continual reassessment method (CRM) used to determine dose changes with a target frequency of dose limiting toxicity of 20%. Fatal toxicities were to be scored as a full event; each reversible grade 4 toxicity was scored as 0.5 event, and each reversible grade 3 toxicity was scored as 0.25 event, with a total event score limited to 1 per patient. This method allows more patients to be treated near the MTD for the regimen than traditional dose-finding designs, and can account for a range of severity of dose-limiting toxicities. Results: We accrued a total of 15 subjects (3 to dose level 1, 9 to level 2, and 3 to level 3) before the CRM converged on a recommended phase II dose combination of 30 mg/m2 of liposomal doxorubicin and 20 mg/m2 of temsirolimus. Nine subjects experienced a total of 14 grade 3 or 4 toxicities, 1 at the first dose level, 6 at the second dose level (which became the recommended phase II dose combination), and 2 at the third dose level. Conclusions: The combination of liposomal doxorubicin and temsirolimus is tolerable, with minimal, reversible grade 4 toxicity. A phase II study to determine efficacy for advanced bone and soft tissue sarcomas is ongoing.
TCT-332 Impact of Ultra-Low Contrast Computed Tomography Compared to Three-Dimensional Transesopageal Echocardiography for Transcatheter Aortic Valve Replacement planning
Authors: Nobuyuki Takahashi, Yoshio Kazuno, Yoshio Maeno, Mohammad Kashif, Hiroyuki Kawamori, Kazuaki Okuyama, Yigal Abramowitz, Tarun Chakravarty, Mamoo Nakamura, Wen Cheng, Raj Makkar, Hasan Jilaihawi
Journal: Journal of the American College of Cardiology (2015)
3D Bioprinting: Dual‐Stage Crosslinking of a Gel‐Phase Bioink Improves Cell Viability and Homogeneity for 3D Bioprinting (Adv. Healthcare Mater. 19/2016)
Authors: Karen Dubbin, Yuki Hori, Kazuomori K. Lewis, Sarah C. Heilshorn
Journal: Advanced Healthcare Materials (2016)

Current bioinks for cell-based 3D bioprinting are not suitable for technology scale-up due to the challenges of cell sedimentation, cell membrane damage, and cell dehydration. A new self-assembling bio-ink is designed to enable 3D bio-printing of multiple cell types into an aqueous bath on page 2488 by Sarah C. Heilshorn and co-workers, to overcome these three major hurdles. Artwork designed by Karen Dubbin and Nick Suhar.
Prognostic Value of 18F-FDG Positron Emission Tomography Used for Assessment of the First Line Therapy in 410 Diffuse Large B-Cell Lymphoma Patients: A Daily Practice Evaluation Before and After the Prescription of This Metabolic Imaging Technique,
Authors: Herve Ghesquieres, Céline Ferlay, Emilie Lavergne, Emmanuelle Nicolas Virelizier, Izabela-Irina Domnisoru, Philippe Rey, Thérèse Gargi, Sylvie Chabaud, Catherine Chassagne-Clément, Bertrand Favier, Pierre Biron, Thomas Mognetti, Vanina Isnardi, Catherine Sebban, Jean-Yves Blay, Sébastien Cimarelli
Journal: Blood (2011)
SB431542, An Inhibitor of TGF-β1 Activin Receptor-Like Kinases, Improves the Natural History of Myelofibrosis In Gata1low Mice
Authors: Maria Zingariello, Barbara Ghinassi, Rosa Alba Rana, Maria Verrucci, Fabrizio Martelli, Anna Rita F Migliaccio
Journal: Blood (2010)
GW27-e0590 Ablation of Atrioventricular Nodal Reentrant Tachycardias Using a Three-dimensional Electroanatomical Mapping System: Randomized comparison to conventional radiofrequency catheter ablation
Authors: Zhang Shouwen, Mingfeng Shao, Rongjun Zhang, Fangfang Wu, Xinhua Li
Journal: Journal of the American College of Cardiology (2016)
Lung cancer DSA: A platform for discovery of biomarkers in lung cancer
Authors: A. Tanney, R. Kennedy
Journal: Journal of Clinical Oncology (2008)

22086 Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide with low response rates to standard chemotherapy treatment. Identification of reliable genomics biomarkers that predict progression and response to therapy are likely to improve patient survival. Current genomic tools lack disease focus and are likely to miss potentially important information contained in patients' tissue samples. Methods: Through a combination of large-scale in-house sequencing, gene expression profiling and public sequence and gene expression data mining we have characterised the transcriptome of NSCLC and used this information to create a unique disease focused microarray - Lung Cancer DSA (LCDSA) research tool. Sequence level comparisons were carried out with the Affymetrix HG U-133 Plus2 array, the Agilent Whole Human Genome Array and the Illumina Human 6 array. In addition, a technical assessment experiment was carried out using NSCLC and normal lung samples to identify transcripts of biological interest. Results: The LCDSA identifies approximately 60,000 transcripts relevant to lung cancer. Comparison of the content of the LCDSA research tool with the 3 leading commercial human arrays demonstrated that there were a core set of 15,541 LCDSA research tool unique transcripts that were not detectable by any of these arrays, thus demonstrating the increased coverage of the lung transcriptome by the LCDSA research tool. The results of the technical assessment experiment demonstrated that in total 35,625 transcripts were consistently detected by the LCDSA research tool as being expressed in either the normal or tumor tissue. A comparison of normal lung and tumor tissue identified 2,148 of the unique transcripts as being differentially expressed in NSCLC and therefore potentially biological significant. Conclusions: The LCDSA allows for the study of approximately 60,000 transcripts relevant to lung cancer, of which tens of thousands are unavailable on leading commercial microarrays. We have used this approach to identify novel transcripts that may be important in lung cancer biology. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Almac Diagnotics
GW27-e0702 Toll-like receptor 7 expression and inflammation response in oxidized-low-density lipoprotein-stimulated macrophages
Authors: Huang Weijun, Gaifeng Hu, Huiyu Tong, Meijun Li, Linlin Mai, Dezhu Chen, Jiaqi Tan, Yingwen Chen, Yuli Huang, Yunzhao Hu
Journal: Journal of the American College of Cardiology (2016)
TCT-161 Development of a new prediction rule for chronic total occlusion recanalization failure: The Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS CTO) score
Authors: Georgios Christopoulos, David Kandzari, Robert Yeh, Farouc Jaffer, Dimitri Karmpaliotis, R. Michael Wyman, Khaldoon Alaswad, William Lombardi, J. Aaron Grantham, Jeffrey W. Moses, Georgios E. Christakopoulos, Muhammad Nauman J Tarar, Bavana V. Rangan, Nicholas Lembo, Santiago Garcia, Daisha Cipher, Craig Thompson, Subhash Banerjee, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2015)
TCT-714 Transcatheter mitral valve replacement with balloon expandable valves in native mitral valve disease due to severe mitral annular calcification: Results from the first global registry
Authors: Mayra Guerrero, Danny Dvir, Dominique Himbert, Marina Urena, Vaikom S. Mahadevan, Mackram Eleid, Daniel O'Hair, Pedro Martinez-Clark, Adam Witkowski, Olaf Wendler, Josep Rodes-Cabau, Nicolas Dumonteil, Enrico Ferrari, Daniel Ciaburri, William M. Suh, Gabriel Vorobiof, Adam Greenbaum, Dee Dee Wang, Gaetano Paone, Jose Honorio Palma, Antonio E. Dager, Axel Linke, Ran Kornowski, Georg Nickenig, Alain G. Cribier, Vinayak Bapat, Charanjit Rihal, Alec Vahanian, Webb John, William W. O'Neill
Journal: Journal of the American College of Cardiology (2015)
TCT-438 Radial Versus Femoral Access for Primary Percutaneous Interventions in Elderly Patients. A Systematic Review and Meta-Analysis
Authors: Pedro A. Villablanca Spinetto, Divyanshu Mohananey, Mohammed Makkiya, Arthur Omondi, Ajay Joseph, Oscar Maitas, Irving E. Perez Guzman, Afiachukwu Onuegbu, Peter P. Vlismas, Mohsin Salih, Mohammed Algodi, David Briceno
Journal: Journal of the American College of Cardiology (2015)
TCT-249 Hypoxic Liver Injury at Admission as a Predictor of In-hospital Death in Patients with ST-Elevation Myocardial Infarction (STEMI) undergone Primary percutaneous coronary intervention (PCI): Data from INTERSTELLAR cohort
Authors: Hyun Woo Park, Ho-Jun Jang, Tae-Hoon Kim, Jon Suh, Sang-Don Park, Woong Chol Kang, Jeonggeun Moon, Pyung Chun Oh, Hyung Oh Choi, Yoon Haeng Cho, Sung Woo Kwon
Journal: Journal of the American College of Cardiology (2015)
Comment on Bordeleau et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366
Authors: Marjolein M.J. Zanders, Andrew G. Renehan, Samantha L. Bowker, Bendix Carstensen, Lonneke V. van de Poll-Franse, Jeffrey A. Johnson
Journal: Diabetes Care (2014)

The recent findings from the Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial that insulin glargine has a neutral association with cancer outcomes are, as Bordeleau et al. (1) state, “reassuring,” but we suggest that they are not yet conclusive.

Observational studies initially supported the hypothesis that glargine is linked with an increased cancer risk. Many of the earlier studies were justifiably criticized for methodological limitations and were arguably inconclusive. Results from the ORIGIN trial (2) seemed to bring a clearer picture. Although cancer was a post hoc end point, the findings were relevant: no differences between treatment arms for all cancer incidence or deaths, or …
Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel.
Journal: Circulation (1992)

BACKGROUND Lipid and lipoprotein profiles of coronary heart disease (CHD) patients have usually not included data on high density lipoprotein cholesterol (HDL-C), except in small groups, and have not included information on women. Both aspects are meaningful in the evaluation of patients for risk classification and for the importance of HDL-C in dictating further evaluation. METHODS AND RESULTS In the screening phase of a clinical trial, we obtained lipid and lipoprotein levels under Centers for Disease Control-standardized procedures in more than 6,700 men and 1,500 women aged 40-72 years. Mean total cholesterol (TC) was higher in women (by 15-24 mg/dl) but changed little with age. Mean HDL-C, however, progressively increased with increased age for both sexes (34.4 at age of less than 50 years to 37.5 mg/dl at age 65 or older in men and from 41.3 to 44.5 mg/dl for the respective age groups in women). Triglycerides (TG) were lower in elderly groups, particularly in men (151 mg/dl in 65-year-olds versus 189 in counterparts less than 50 years). The number of previous infarctions, severity of congestive heart failure, and severity of angina were negatively correlated with mean HDL-C in a dose-response manner, whereas the association with mean TG was inverted, creating a mirror image of that observed with HDL-C. More than half of patients (52%) with TC less than 200 mg/dl exhibited HDL-C levels consistent with the accepted "high-risk" range of less than 35 mg/dl, whereas an increasing percentage of desirable HDL-C level was found with increasing levels of TC (14% with HDL-C greater than or equal to 45 mg/dl at TC less than 200 mg/dl increasing gradually to 28% in patients with TC greater than 260 mg/dl). CONCLUSIONS These results provide previously unavailable information on the lipid profile of female patients and appear to strongly establish the case for obtaining all three standard blood lipid determinations (TC, HDL-C, and TG) in coronary patients as well as in the framework of detecting and classifying individuals at high risk for CHD.
LPL and ADAM-29 Gene Expressions Stratify Prognosis in Clinical Stage BinetA and B Chronic Lymphocytic Leukemia Patients
Authors: Wolney Góis Barreto, Lorenza Oliveira Belluzzi, Grazziella Curado Siufi, Marçal Cavalcante de Andrade Silva, Eliza Yuriko Sugano Kimura, Yuri Vasconcelos, Inara Lucia Arce, Mihoko Yamamoto
Journal: Blood (2008)
Comparison of Outcomes in Chronic Lymphocytic Leukemia (CLL) with the Addition of Rituximab to Initial Treatment: A Comparative Effectiveness Analysis in the Province of British Columbia (BC), Canada
Authors: Lauren J. Lee, Alina S. Gerrie, Helene Bruyere, Tanya L. Gillan, Stephen J.T. Huang, Cynthia L. Toze, Khaled M. Ramadan
Journal: Blood (2014)
Vaccination with the PR1 Leukemia-Associated Antigen Can Induce Complete Remission in Patients with Myeloid Leukemia.
Authors: Muzaffar H. Qazilbash, Eric Wieder, Rosa Rios, Sijie Lu, Shreya Kant, Sergio Giralt, Elihu H. Estey, Peter Thall, Marcos de Lima, Daniel Couriel, Richard E. Champlin, Krishna Komanduri, Jeffrey J. Molldrem
Journal: Blood (2004)
Front-Line Treatment of Low-Grade Non-Follicular Non-Hodgkin Lymphoma (Final Report of Gisl LL02 Trial).
Authors: Maria Goldaniga, Francesco Merli, Caterina Stelitano, Vincenzo Callea, Fiorella Ilariucci, Mario Russo, Patrizio Mazza, Stefano Luminari, Francesca Rossi, Maura Brugiatelli, Dimitri Luisi, Barbara Olivero, Giorgio Lambertenghi Deliliers, Massimo Federico, Luca Baldini
Journal: Blood (2007)
Genome-Wide Association Study Identifies Genetic Loci Associated with Iron Deficiency.
Authors: Christine E. McLaren, Chad P. Garner, Clare C. Constantine, Stela Masle, Christopher D. Vulpe, Beverly M. Snively, James D. Cook, Deborah A. Nickerson, Catherine Leiendecker-Foster, Kenneth B. Beckman, John H. Eckfeldt, Victor R. Gordeuk, Joseph A. Murray, Paul C. Adams, Lisa F. Barcellos, Anthony A. Killeen, Katrina Goddard, David M. Reboussin, Gordon D. McLaren
Journal: Blood (2009)
Multiple Neoplasms Simultaneously Diagnosed by Complementary Triple-Tracer PET/CT and 123I-MIBG Scintigraphy
Authors: Esben Søndergaard, Andreas Ebbehoj, Per Løgstrup Poulsen, Lars Christian Gormsen
Journal: Clinical Nuclear Medicine (2016)

A 51-year-old woman with recurrent paragangliomas and catecholamine hypersecretion underwent 18F-FDG PET/CT for localization and evaluation of extent of disease. This revealed multiple 18F-FDG avid tumors with localization pattern suggesting multiple primary neoplasms of different origin rather than disseminated paraganglioma. Three additional nuclear medicine investigations were performed (18F-DOPA PET/CT, 68Ga-DOTATOC PET/CT and 123I-MIBG scintigraphy) to further characterize tumor biology, guide diagnostic workup, and decide treatment strategy. Biopsies showed benign paraganglioma, mucinous adenocarcinoma of the cecum, renal cell carcinoma, and thyroid colloid nodule. Treatment strategy was based on tumor biology determined by the various PET and SPECT tracers used.
TCT-152 EURYDICE Registry: European Direct Aortic CoreValve Experience
Authors: Giuseppe Bruschi, Hafid Amrane, Bernard Chevalier, Giuseppe Coletti, Piotr Branny, Domenico Mazzitelli, Neil Moat, Thomas Modine, Johan M. Bosmans, Stephen Brecker, Michael Horst, Didier Tchetche, Nick Bouboulis, Saib Khogali, Bertrand Marcheix, Uday Trivedi, Haim Danenberg, Peter den Heijer, Corrado Lettieri, Federico De Marco, A.J. van Boven, Claudia Fiorina, Marian Branny, Ruediger Lange, Sam Firoozi, Konstantinos Spargias, Francesco Della Rosa, Nicolas Dumonteil, David Hildick-Smith, Amir Elami, Vinicio Fiorani, Otto Dapunt, Hasan Bushnaq
Journal: Journal of the American College of Cardiology (2015)
TCT-198 Assessment Of Aortic Valve Location On Supine Chest X-ray. Applicability Of The Aortic Valve Location Ratio For Assessment Of Intra-cardiac Assist Device Position
Authors: Dagmar M. Ouweneel, Krischan D. Sjauw, Esther M. Wiegerinck, Alexander Hirsch, Jan Baan, Bas A.J.M. De Mol, Wim K. Lagrand, R. Nils Planken, Jose P. Henriques
Journal: Journal of the American College of Cardiology (2015)
GW27-e0564 The role of Hypoxia-Inducible Factor 1-Alpha (HIF1-α) in maintaining the balance between survival and cell death during the course of myocardial infraction.
Authors: Angelos Tsipis, Anna Maria Athanassiadou, Emmanouil Petrou, Dimitrios Miliopoulos, Aggeliki Gkouziouta, Pauline Athanassiadou, Polixeni Nikolopoulou
Journal: Journal of the American College of Cardiology (2016)
TCT-73 Impact of Routine MicroNet-Covered Embolic Prevention Stent System Use on Contemporary Carotid Revascularization: All-Comer PARADIGM Study
Authors: Piotr Musialek, Adam Mazurek, Mariusz Trystula, Anna Borratynska, Agata Lesniak-Sobelga, Malgorzata Urbanczyk, Robert P. Banys, Andrzej Brzychczy, Lukasz Partyka, Krzysztof F. Zmudka, Piotr Podolec
Journal: Journal of the American College of Cardiology (2015)
Clonal Evolution of Malignant Populations In Potentially Biclonal Chronic Lymphocytic Leukemia Patients
Authors: Karla Plevova, Hana Skuhrova Francova, Boris Tichy, Jitka Malcikova, Sarka Pavlova, Ondrej Horky, Olga Stehlikova, Michael Doubek, Yvona Brychtova, Jiri Mayer, Sarka Pospisilova
Journal: Blood (2010)
TCT-464 Long-Term Mortality Of Percutaneous Coronary Intervention With Drug-Eluting Stents Compared To Bypass Surgery In Patients With Left Main Disease Stratified By The SYNTAX Score: Comprehensive Systematic Review And Meta-Analysis Of 3372 Patients
Authors: Kleanthis Theodoropoulos, Marco G. Mennuni, Aakash Garg, Abhishek Sharma, Giulio G. Stefanini
Journal: Journal of the American College of Cardiology (2015)